Core Insights - Amgen Inc. is a leading biotechnology company engaged in innovative therapies and treatments, operating in a competitive landscape with peers like Biogen and Gilead Sciences [1] Investment Activity - Atlantic Union Bankshares Corp increased its investment in Amgen by 66.3% in Q3, now holding 17,698 shares valued at approximately $5 million, reflecting strong investor confidence [2] - Legacy Investment Solutions LLC and Evelyn Partners Investment Management LLP have acquired new stakes in Amgen, valued at around $27,000 and $32,000 respectively, indicating growing interest in the company's potential [3] - Quaker Wealth Management LLC increased its position in Amgen by 200% in Q2, further demonstrating the rising interest among investors [3] - Atle Fund Management AB reduced its holdings in Amgen by 42.2% in Q3, now owning 13,806 shares valued at approximately $3.9 million, showcasing varied investment strategies [4] Stock Performance - Amgen's stock is currently trading at $343.63, with a slight decrease of $1.16 or -0.34% today, and has experienced a 52-week high of $353.25 and a low of $261.43 [5] - The company maintains a solid market capitalization of approximately $185 billion, reinforcing its status as a key player in the biotechnology sector [5][6]

Charles Schwab slightly missed analyst expectations with its fourth-quarter earnings report Wednesday, but the stock rose anyway. Investors likely were cheered by strong growth in earnings, revenue, and new assets. Core net new assets were $163.9 billion for the quarter, and total client assets grew to $11.9 trillion. Schwab has benefited from a surge in investor activity that creates a tailwind for the company in 2026. ...